Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients

Abstract Background Despite the high response rate to PD-1 blockade therapy in metastatic melanoma (MM) patients, a significant proportion of patients do not respond. Identifying biomarkers to predict patient response is crucial, ideally through non-invasive methods such as liquid biopsy. Methods So...

Full description

Saved in:
Bibliographic Details
Main Authors: Amalia Azzariti, Simona De Summa, Tommaso M. Marvulli, Ivana De Risi, Giuseppe De Palma, Roberta Di Fonte, Rossella Fasano, Simona Serratì, Sabino Strippoli, Letizia Porcelli, Michele Guida
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Metastatic melanoma
Predictor of anti-PD1 response
Anti-PD1 resistance
sPD1
sPD-L1
sLAG-3
Online Access:https://doi.org/10.1186/s13046-025-03306-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13046-025-03306-w

Similar Items